ANAB — ANAPTYSBIO INC (Healthcare >> Biotechnology)
ANAB FAQ
What is ANAB's P/E ratio?
ANAPTYSBIO INC (ANAB) currently trades at a P/E ratio of 26.28.
What is ANAB's ROE?
ANAPTYSBIO INC reports a Return on Equity (ROE) of -210.14%.
What is ANAB's dividend yield?
ANAPTYSBIO INC offers a dividend yield of 0.00%.
What is ANAB's Deepscope Quality Score?
Deepscope rates ANAB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANAB?
Deepscope's AI Timing Score for ANAB is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANAB belong to?
ANAPTYSBIO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 56.77
Price
-0.84
(-1.46%)
Day Change
|
|
|---|
ANAB Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 56.77 |
| PBV / Sector |
133.45 / 4.95
|
| Earning Per Share | -0.89 |
| PE / Sector |
26.28 / 18.41
|
| PEG or PE/Growth / Sector |
-1.06 / 0.63
|
| Average 1M Daily Value |
27.64 M
GREAT
|
| Average 1W Daily Value |
28.46 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-18 09:54:11 |
| Symbol | ANAB |
| Name | ANAPTYSBIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.10 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,701.09 / 9,037.96 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
Phone: 858 362 6295
Website: https://www.anaptysbio.com
Employees: 104
Sector: Healthcare >> Biotechnology
Description: AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google